A study highlighted the accuracy of three leading continuous glucose monitors (CGM), including systems from Abbott and Dexcom.

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

Oncology studies present unique challenges when it comes to participant treatment, resupply, and study management.

Rene Haas was on an exercise bike two weeks ago watching CNBC like he does every morning, when the tech sector took a beating ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump. In this article, we are going to take ...

Asked what the weather is like outside, one ... research implies that the robot may be even less humanoid than Amazon’s. Rumors surrounding the upcoming release have described the hub as “a ...

Arm Holdings plc excels in the semiconductor space by licensing its IP to major partners like Nvidia, Microsoft, and Oracle. Despite recent bearish trends, Arm's financials show a promising ...

Investors were expecting Arm to raise its full-year outlook with the adoption of its chip designs for AI servers, and with increased use of its higher royalty rate Armv9 design for smartphones, Summit ...

Cody Acree from Benchmark Co. reiterated a Hold rating on ARM Holdings PLC ADR (ARM – Research Report). The company’s shares opened today at $162.00. Leverage the power of TipRanks' Smart ...

Thomas O’Malley from Barclays maintained a Buy rating on ARM Holdings PLC ADR (ARM – Research Report), with a price target of $155.00. The company’s shares closed yesterday at $173.26.

Investors were expecting Arm to raise its full-year outlook with the adoption of its chip designs for AI servers, and with increased use of its higher royalty rate Armv9 design for smartphones ...

Ideal for high-performance mobile handsets, networking and auto-infotainment devices. ARM Cortex-A9 processor: A traditional single core processor for simplified design migration in high-performance, ...